Literature DB >> 2457648

The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV.

E A Kabat1, J Liao, E F Osserman, A Gamian, F Michon, H J Jennings.   

Abstract

The fine structure of the combining site of human mAb IgMNOV to poly-alpha(2----8)linked NeuNAc, the epitope of the group B meningococcal and E. coli K1 polysaccharides, has been probed using RIA and ELISA. Inhibition by oligomers ranging from 2 to 12 residues was used to assay binding to IgMNOV by group B meningococcal polysaccharide preparations (GBMP) or by poly(A). The inhibitory properties of the oligomers were almost identical in both assays of the binding of GBMP to horse IgM (H46). This evidence and the finding that both GBMP and poly(A) precipitated IgMNOV equally per unit weight indicated that the epitope of poly(A) must mimic an equivalent epitope on GBMP despite the absence of any apparent common structural features in the two molecules. Unlike most carbohydrate-anticarbohydrate systems in which the site is saturated by oligomers of up to six or seven sugars, all the anti-alpha(2----8)NeuNAc systems above required much larger oligomers. Because these oligomers are larger than the maximum size of an antibody site the epitope must be conformationally controlled, and this has been confirmed by nuclear magnetic resonance spectroscopy. However, despite the above similarities, GBMP and poly(A) were differentiated in that only GBMP bound to H46. Smaller linear molecules obtained by delipidating the GBMP, as well as periodate-oxidized GBMP with its nonreducing end oxidized or linked covalently to BSA, bound to and precipitated IgMNOV and H46. This showed that, despite their differences, terminal nonreducing ends were not involved and that both epitopes were located in the conformationally controlled inner residues of the GBMP. The difference thus must reside in the ability of IgMNOV and H46 to recognize different structural aspects of the same conformationally controlled inner residues. The ELISA data indicate that both IgMNOV and H46 have groove-type sites that bind exclusively to an epitope located on the acidic side of the inner residues. The differences determining the ability of IgMNOV and the failure of H46 to cross-react with poly(A), poly(I), and denatured DNA, may depend on differences in the degree of protonation required by each antibody, and this may be clarified by a study of the effects of pH on the precipitin behavior of IgMNOV and H46.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457648      PMCID: PMC2188997          DOI: 10.1084/jem.168.2.699

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  A structural model for the polyadenylic acid single helix.

Authors:  W Saenger; J Riecke; D Suck
Journal:  J Mol Biol       Date:  1975-04-25       Impact factor: 5.469

2.  Effect of pH on the precipitin reaction of human monoclonal macroglobulins with specificity for Klebsiella K polysaccharides containing 3,4-pyruvylated D-galactose and 4,6-pyruvylated D-galactose.

Authors:  A S Rao; E A Kabat; W Nimmich; E F Osserman
Journal:  Mol Immunol       Date:  1982-04       Impact factor: 4.407

3.  Precipitating cross-reactions among pneumococcal types.

Authors:  M Heidelberger
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

4.  Conformational and dynamic differences between N. meningitidis serogroup B and C polysaccharides, using n.m.r. spectroscopy and molecular mechanics calculations.

Authors:  J C Lindon; J G Vinter; M R Lifely; C Moreno
Journal:  Carbohydr Res       Date:  1984-10-01       Impact factor: 2.104

5.  Immunochemical studies on human monoclonal macroglobulins with specificities for 3,4-pyruvylated D-galactose and 4,6-pyruvylated D-glucose.

Authors:  A S Rao; J Liao; E A Kabat; E F Osserman; M Harboe; W Nimmich
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

6.  Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.

Authors:  H J Jennings; C Lugowski
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

7.  Lipid on capsular polysaccharides of gram-negative bacteria.

Authors:  E C Gotschlich; B A Fraser; O Nishimura; J B Robbins; T Y Liu
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

8.  Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. Involvement of a long oligosaccharide segment in molecular interactions of polysialic acid.

Authors:  J Finne; P H Mäkelä
Journal:  J Biol Chem       Date:  1985-01-25       Impact factor: 5.157

9.  Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide.

Authors:  C Moreno; M R Lifely; J Esdaile
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

10.  Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran.

Authors:  J Cisar; E A Kabat; M M Dorner; J Liao
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

View more
  18 in total

1.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Specificity of the immune response to the group B polysaccharide of Neisseria meningitidis.

Authors:  M R Lifely; J Esdaile
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

3.  Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.

Authors:  L C Paoletti; D L Kasper; F Michon; J DiFabio; H J Jennings; T D Tosteson; M R Wessels
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

4.  Common cleavage pattern of polysialic acid by bacteriophage endosialidases of different properties and origins.

Authors:  S Pelkonen; J Pelkonen; J Finne
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  An antibody Fab selected from a recombinant phage display library detects deesterified pectic polysaccharide rhamnogalacturonan II in plant cells.

Authors:  M N Williams; G Freshour; A G Darvill; P Albersheim; M G Hahn
Journal:  Plant Cell       Date:  1996-04       Impact factor: 11.277

6.  Evidence for helical structure in a tetramer of α2-8 sialic acid: unveiling a structural antigen.

Authors:  Marcos D Battistel; Michael Shangold; Loc Trinh; Joseph Shiloach; Darón I Freedberg
Journal:  J Am Chem Soc       Date:  2012-06-22       Impact factor: 15.419

7.  The conformational properties of methyl alpha-(2,8)-di/trisialosides and their N-acyl analogues: implications for anti-Neisseria meningitidis B vaccine design.

Authors:  Austin B Yongye; Jorge Gonzalez-Outeiriño; John Glushka; Verena Schultheis; Robert J Woods
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

8.  A specific, high-affinity binding site for the hepta-beta-glucoside elicitor exists in soybean membranes.

Authors:  J J Cheong; M G Hahn
Journal:  Plant Cell       Date:  1991-02       Impact factor: 11.277

9.  Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.

Authors:  E Alonso de Velasco; A F Verheul; A M van Steijn; H A Dekker; R G Feldman; I M Fernández; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

10.  Relation between structure and immunologic properties of the Vi capsular polysaccharide.

Authors:  S C Szu; X R Li; A L Stone; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.